Abstract:
Immune-mediated inflammatory diseases (IMIDs) are heterogenous diseases targeting different organs/tissues such as the joints or the skin that often share a common inflammatory pathway. This presentation will give a broad overview of the risk factors for developing IMIDs, their pathogenesis, advanced biologic therapies and how immunogenicity affects response.
As with small molecules, there is variability in response to monoclonal antibodies between patients. This presentation will explain how this variability can be studied by analyzing their dose-concentration-effect relationships, the mechanisms of which are different from those of small molecules.
Dr James Bluett, The University of Manchester, UK
Dr James Bluett (MBBS, MRes, MSc, PhD; Orchid ID: https://orcid.org/0000-0001-5062-5779) is a senior clinical lecturer and honorary consultant in rheumatology at the University of Manchester. James has a specialist interest in interventions to improve treatment response in inflammatory arthritis and is an experienced chief investigator. In 2016 he completed his PhD investigating methotrexate adherence in rheumatoid arthritis and the genetics of methotrexate-pneumonitis. He oversees a large multi-centre observational psoriatic arthritis study (OUTPASS). He has presented his research at national and international conferences and has collaborated internationally.
Gilles Paintaud, Tours University Hospital, France
Gilles Paintaud 
is professor of clinical pharmacology at the Faculty of Medicine of Tours and works in the unit of therapeutic drug monitoring and analytical toxicology of Tours University Hospital, France. He is physician and started as a gastroenterologist before moving to pharmacology. He obtained his PhD at the Karolinska Institute in Stockholm. He has been working on the pharmacokinetics of therapeutic antibodies since 2001 and he is the head of the only French Reference Medical Laboratory for therapeutic drug monitoring of monoclonal antibodies.
His research focuses on the interindividual variability of the response to monoclonal antibodies, using in-house ELISA techniques and population pharmacokinetic and pharmacokinetic-pharmacodynamic (PK-PD) modeling.